New drugs in gynecologic cancer

Curr Treat Options Oncol. 2001 Apr;2(2):119-28. doi: 10.1007/s11864-001-0054-0.

Abstract

The implementation of new drug treatments has improved the prognosis for advanced cancers of the cervix, uterus, and ovary. Platinum analogs are the most effective drugs in the treatment of ovarian cancer. Other drugs, such as oxaliplatin, have been proposed as a rational treatment of platinum refractory ovarian cancer. Epothilones are also being studied in clinical trials, as are histone deacetylase inhibitors. Several promising agents may soon receive Food and Drug Administration approval.

Publication types

  • Review

MeSH terms

  • Aminopyridines / administration & dosage
  • Anti-Bacterial Agents / administration & dosage
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Boronic Acids / administration & dosage
  • Bortezomib
  • Cisplatin / analogs & derivatives
  • Female
  • Gefitinib
  • Genital Neoplasms, Female / drug therapy*
  • Humans
  • Hydroxamic Acids / administration & dosage
  • Lactams, Macrocyclic
  • Organoplatinum Compounds / administration & dosage
  • Paclitaxel / administration & dosage
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrazines / administration & dosage
  • Quinazolines / administration & dosage
  • Trastuzumab

Substances

  • Aminopyridines
  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Boronic Acids
  • Hydroxamic Acids
  • Lactams, Macrocyclic
  • Organoplatinum Compounds
  • Pyrazines
  • Quinazolines
  • amminedichloro(2-methylpyridine)platinum(II)
  • pyroxamide
  • Bortezomib
  • Protein-Tyrosine Kinases
  • BBR 3464
  • Trastuzumab
  • Paclitaxel
  • Cisplatin
  • Gefitinib